Regulatory strategy and approval processes considered for PEG-drug conjugates and other nanomedicines

  • Tacey X. Viegas
  • Francesco M. Veronese
Part of the Milestones in Drug Therapy book series (MDT)


Therapeutic products prepared by PEG conjugation currently undergo the same regulatory scrutiny as small molecule drugs. A brief review of historical and current regulatory submission strategies is dis cussed in this chapter. In addition, some forward looking suggestions and considerations are made for nanomedicines that employ PEG and other polymers.


Approval Process Small Molecule Drug Interferon Alpha2b Physician Desk Reference High Antiviral Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    ESF Scientific Forward Look on Nanomedicines, 23 February 2005, ( Scholar
  2. 2.
    Duncan R (2003) The dawning era of polymer therapeutics. Nat Rev Drug Discov 2: 347–360CrossRefPubMedGoogle Scholar
  3. 5.
    Grace M, Youngster S, Gitlin G, Sydor W, Xie L, Westreich L, Jacobs S, Brassard D, Bausch J, Bordens R (2001) Structural and biologic characterization of pegylated recombinant IFN-alpha 2b. J Interferon Cytokine Res 12: 1103–1115CrossRefGoogle Scholar
  4. 6.
    Dhalluin C, Ross A, Leuthold LA, Foser S, Gsell B, M, ller F, Senn H (2005) Structural and bio physical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional iso mers. Bioconjug Chem 16: 504–517CrossRefPubMedGoogle Scholar
  5. 7.
    Foser S, Schacher A, Weyer KA, Brugger D, Dietel E, Marti S, Schreitm, ller T (2003) Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interfer on alpha-2a (PEGASYS). Protein Expr Purif 30: 78–87CrossRefPubMedGoogle Scholar
  6. 8.
    Gaspar R, Duncan R (2009) Polymer carriers: Preclinical safety and regulatory implications for design and development of polymer therapeutics. ADDR Theme issue: Polymer Therapeutics: Clinical applications and Challenges for Development (in press)Google Scholar
  7. 9.
    Burgess DJ, Hussain AS, Ingallinera TS, Chen ML (2002) Assuring quality and performance of sustained and controlled release parenterals: AAPS workshop report, co-sponsored by FDA and USP. Pharm Res 19: 1761–1768CrossRefPubMedGoogle Scholar
  8. 10.
    Yamaoka T, Tabata Y, Ikada Y (1994) Distribution and tissue uptake of Poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 83: 601–606CrossRefPubMedGoogle Scholar
  9. 11.
    Conover C, Lejeune L, Linberg R, Shum K, Shorr RGL (1996) Transitional vacuole formation following a bolus infusion of PEG-hemoglobin in the rat. Art Cells, Blood Subs and Immob Biotech 24: 599–611CrossRefGoogle Scholar
  10. 12.
    Bendele B, Seely J, Richey C, Sennello G, Shopp G (1998) Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicological Sciences 42: 152–157CrossRefPubMedGoogle Scholar
  11. 13.
    Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, Garratty G (2007) Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110: 1103–1111CrossRefGoogle Scholar
  12. 14.
    Hamad I, Hunter AC, Szebeni J, Moghimi SM (2008) Poly(ethylene glycol)s generate comple ment activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol Immuno 46: 225–232CrossRefGoogle Scholar
  13. 15.
    Moghimi SM, Hamad I, Andresen TL, Jørgensen K, Szebeni J (2006) Methylation of the phos phate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatox in production. FASEB J 20: 2591–2593CrossRefPubMedGoogle Scholar
  14. 17.
    Nachtmann F (2008) The regulatory situation of biosimilars/follow-on-biologics: a pioneer’s perspective. AAPS Annual Meeting and Exposition, Atlanta, GA, November 1817.Google Scholar
  15. 19.
    Faunce T, Shats K (2007) Researching safety and cost-effectiveness in the life cycle of nanomedicine. J Low Med 15: 128–135Google Scholar
  16. 21.
    EMEA, Reflection paper on nanotechnology-based medicinal products for human use, (EMEA/CHMP/79769/2006), 29 June 2006Google Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2009

Authors and Affiliations

  • Tacey X. Viegas
    • 1
  • Francesco M. Veronese
    • 2
  1. 1.Serina Therapeutics, Inc.HuntsvilleUSA
  2. 2.Department of Pharmaceutical SciencesUniversity of PaduaPaduaItaly

Personalised recommendations